CASI Pharmaceuticals, Inc.
CASI
$1.33
-$0.035-2.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.37M | 28.54M | 22.06M | 23.10M | 28.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.37M | 28.54M | 22.06M | 23.10M | 28.94M |
| Cost of Revenue | 18.41M | 17.39M | 10.08M | 9.98M | 12.05M |
| Gross Profit | 12.96M | 11.15M | 11.98M | 13.12M | 16.89M |
| SG&A Expenses | 44.81M | 41.44M | 41.09M | 38.52M | 40.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -7.00K | -2.00K | -5.06M | -5.06M | -6.37M |
| Total Operating Expenses | 71.59M | 67.75M | 53.68M | 51.89M | 56.17M |
| Operating Income | -40.23M | -39.21M | -31.62M | -28.79M | -27.23M |
| Income Before Tax | -40.48M | -39.26M | -30.78M | -26.85M | -30.04M |
| Income Tax Expenses | -- | -- | -1.00K | -1.00K | -81.00K |
| Earnings from Continuing Operations | -40.48 | -39.26 | -30.78 | -26.85 | -29.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -163.00K | -332.00K | -501.00K |
| Net Income | -40.48M | -39.26M | -30.94M | -27.18M | -30.46M |
| EBIT | -40.23M | -39.21M | -31.62M | -28.79M | -27.23M |
| EBITDA | -37.19M | -35.82M | -27.88M | -25.37M | -24.15M |
| EPS Basic | -2.51 | -2.53 | -2.23 | -2.03 | -2.28 |
| Normalized Basic EPS | -1.65 | -1.67 | -1.48 | -1.31 | -1.32 |
| EPS Diluted | -2.51 | -2.53 | -2.23 | -2.03 | -2.28 |
| Normalized Diluted EPS | -1.65 | -1.67 | -1.48 | -1.31 | -1.32 |
| Average Basic Shares Outstanding | 63.46M | 61.35M | 55.57M | 53.66M | 53.48M |
| Average Diluted Shares Outstanding | 63.46M | 61.35M | 55.57M | 53.66M | 53.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |